Skip to main navigation
Skip to search
Skip to main content
The Hebrew University of Jerusalem Home
Approve / Request updates on publications
Link opens in a new tab
Search content at The Hebrew University of Jerusalem
Home
Profiles
Research units
Research output
Prizes
Paclitaxel (TAXOL®) therapy in ovarian carcinoma
C. Caldas
, W. P. McGuire
*
*
Corresponding author for this work
Research output
:
Contribution to journal
›
Article
›
peer-review
29
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Paclitaxel (TAXOL®) therapy in ovarian carcinoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Paclitaxel
100%
Ovarian Carcinoma
100%
Cisplatin
33%
Dose Escalation
22%
Platinum-resistant Disease
22%
Pharmacokinetics
11%
Granulocyte Colony-stimulating Factor (G-CSF)
11%
Response Rate
11%
Neurotoxicity
11%
Ovarian Cancer
11%
Hematologic
11%
Cyclophosphamide
11%
Randomized Trial
11%
Clinical Investigation
11%
Survival Data
11%
Antineoplastic Agents
11%
Residual Disease
11%
Intraperitoneal Administration
11%
Phase I Study
11%
Advanced Disease
11%
Clinical Development
11%
Cause of Death
11%
Hematotoxicity
11%
Most Common Cause
11%
Platinum-based Chemotherapy
11%
Recurrent Disease
11%
Primary Therapy
11%
Gynecologic Malignancies
11%
Canadian Studies
11%
Dose-dependent
11%
Treatment Lines
11%
Toxicity Data
11%
Multi-institutional
11%
Refractory Ovarian Cancer
11%
Bulky Disease
11%
Debulking Surgery
11%
European Canadians
11%
Primary Management
11%
Platinum-resistant
11%
Pharmacology, Toxicology and Pharmaceutical Science
Paclitaxel
100%
Ovary Carcinoma
100%
Diseases
55%
Platinum
44%
Cisplatin
33%
Ovary Cancer
22%
Recurrent Disease
11%
Cyclophosphamide
11%
Granulocyte Colony Stimulating Factor
11%
Anticarcinogen
11%
Minimal Residual Disease
11%
Chemotherapy Regimens
11%
Pharmacokinetics
11%